New stem cell approach could fix immune systems in kids
NCT ID NCT02990819
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial tests a stem cell transplant from unrelated or partially matched family donors for children and young adults with severe immune deficiencies. The stem cells are specially processed to remove certain immune cells, aiming to reduce complications. The goal is to see if this approach leads to stable donor cell engraftment and improved survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stem cell transplant with alpha/beta T and CD19+ cell depletion
- What this could lead to
- If successful, this could provide a safer way to restore immune function in children with life-threatening immune disorders using donor stem cells.
- What could go wrong
- This is an early Phase II trial with only 60 participants, so results may not apply to everyone. Risks include graft failure, graft-versus-host disease, and infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRANULOMATOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill tame a rare immune disease?
- New stem cell processing method offers hope for patients without a perfect donor match
- Second chance: milder prep for stem cell transplants may help when first fails
- Suicide Gene-Equipped t cells aim to make stem cell transplants safer
- Engineered t cells with a kill switch aim to make stem cell transplants safer
- Newborn screening study aims to catch rare diseases at birth